Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving pd-1/ pd-l1 inhibitors

HIGHLIGHTS

• who: August et al. from the University, China have published the Article: Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/ PD-L1 inhibitors, in the Journal: (JOURNAL)
• what: The authors aimed to investigate the association between irAEs and hypertension.

SUMMARY

Endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Jain et_al, 2006; Ranpura et_al, 2010; Syrigos et_al, 2011) and certain small molecular inhibitors of tyrosine kinase (sunitinib, sorafenib, and pazopanib) (Riely and Miller, 2007). Anti-tumor treatments also generate a series of unique dysimmune toxicities . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.